91 related articles for article (PubMed ID: 28668838)
1. Down-regulation of the Tumor Suppressor CYLD Enhances the Transformed Phenotype of Human Breast Cancer Cells.
Orfanidou T; Xanthopoulos K; Dafou D; Pseftogas A; Hadweh P; Psyllaki C; Hatzivassiliou E; Mosialos G
Anticancer Res; 2017 Jul; 37(7):3493-3503. PubMed ID: 28668838
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
3. CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
Yin L; Liu S; Li C; Ding S; Bi D; Niu Z; Han L; Li W; Gao D; Liu Z; Lu J
Tumour Biol; 2016 Sep; 37(9):12731-12742. PubMed ID: 27448305
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity.
Ishikawa Y; Tsunoda K; Shibazaki M; Takahashi K; Akasaka T; Masuda T; Maesawa C
Int J Oncol; 2012 Jul; 41(1):53-60. PubMed ID: 22469839
[TBL] [Abstract][Full Text] [Related]
6. Suppressive role of miR-502-5p in breast cancer via downregulation of TRAF2.
Sun LL; Wang J; Zhao ZJ; Liu N; Wang AL; Ren HY; Yang F; Diao KX; Fu WN; Wan EH; Mi XY
Oncol Rep; 2014 May; 31(5):2085-92. PubMed ID: 24677135
[TBL] [Abstract][Full Text] [Related]
7. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.
Brummelkamp TR; Nijman SM; Dirac AM; Bernards R
Nature; 2003 Aug; 424(6950):797-801. PubMed ID: 12917690
[TBL] [Abstract][Full Text] [Related]
8. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells.
Fiucci G; Ravid D; Reich R; Liscovitch M
Oncogene; 2002 Apr; 21(15):2365-75. PubMed ID: 11948420
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of CYLD in human colon and hepatocellular carcinomas.
Hellerbrand C; Bumes E; Bataille F; Dietmaier W; Massoumi R; Bosserhoff AK
Carcinogenesis; 2007 Jan; 28(1):21-7. PubMed ID: 16774947
[TBL] [Abstract][Full Text] [Related]
11. Effects and mechanism of downregulation of COX‑2 expression by RNA interference on proliferation and apoptosis of human breast cancer MCF‑7 cells.
Han H; Yang S; Lin SG; Xu CS; Han ZH
Mol Med Rep; 2014 Dec; 10(6):3092-8. PubMed ID: 25323004
[TBL] [Abstract][Full Text] [Related]
12. The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene.
Wang L; Baiocchi RA; Pal S; Mosialos G; Caligiuri M; Sif S
Mol Cell Biol; 2005 Sep; 25(18):7953-65. PubMed ID: 16135788
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation.
Zhang YW; Nasto RE; Varghese R; Jablonski SA; Serebriiskii IG; Surana R; Calvert VS; Bebu I; Murray J; Jin L; Johnson M; Riggins R; Ressom H; Petricoin E; Clarke R; Golemis EA; Weiner LM
Oncogene; 2016 Mar; 35(13):1643-56. PubMed ID: 26165839
[TBL] [Abstract][Full Text] [Related]
15. PAX5alpha enhances the epithelial behavior of human mammary carcinoma cells.
Vidal LJ; Perry JK; Vouyovitch CM; Pandey V; Brunet-Dunand SE; Mertani HC; Liu DX; Lobie PE
Mol Cancer Res; 2010 Mar; 8(3):444-56. PubMed ID: 20197384
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of proliferation and migration of human umbilical vein endothelial cells by knockdown of cylindromatosis (CYLD) gene].
Wang X; Li J; Li L; Li X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Aug; 31(8):1027-30. PubMed ID: 26271973
[TBL] [Abstract][Full Text] [Related]
17. Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARβ2 and RASSF1A demethylation.
Li K; Yang J; Han X
Int J Mol Sci; 2014 Dec; 15(12):23519-36. PubMed ID: 25526566
[TBL] [Abstract][Full Text] [Related]
18. Loss of CYLD might be associated with development of salivary gland tumors.
Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.
Pseftogas A; Xanthopoulos K; Siasiaridis A; Poutahidis T; Gonidas C; Tsingotjidou A; Hatzivassiliou E; Mosialos G
Anticancer Res; 2024 May; 44(5):1885-1894. PubMed ID: 38677721
[TBL] [Abstract][Full Text] [Related]
20. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells.
Guo WJ; Zeng MS; Yadav A; Song LB; Guo BH; Band V; Dimri GP
Cancer Res; 2007 Jun; 67(11):5083-9. PubMed ID: 17545584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
